Characterization of CTL Recognized Epitopes on Human Breast Tumors
Annual rept. 19 Aug 1995-18 Aug 1996
TEXAS UNIV AT HOUSTON
Pagination or Media Count:
The overall objective of this proposal is to develop novel therapeutic approaches to breast cancer by understanding the molecular and cellular basis of tumor antigen Ag recognition by cytotoxic T lymphocytes CTL. Characterization of HLA-A2 bound peptides by comparison of CTL activity and signal intensity of peptides by mass-spectrometry has lead to identification of a novel tumor Ag, defined by a peptide epitope from the amino-enhancer of split AES protein. This protein is part of the Notch complex involved in regulation of cell fate during development. This Ag is recognized both by breast and ovarian tumor reactive cell lines. Studies on HER-2 tumor Ag identification and epitope optimization have also led to design of a novel clinical trial with the peptide E75 HER-2 369 - 377 for patients with breast and ovarian cancer. To address the significance of these epitopes we are currently exploring the ability of the corresponding peptides to induce tumor specific immunity.
- Medicine and Medical Research